MMP2 and metabolic syndrome: We can assume that for RPC patients with metabolic syndrome or metabolically healthy obesity, the FABP4+MMP9+MMP2-TIMP1- population of plasma sEVs is the most optimal biomarker reflecting tumor angiogenesis.